نتایج جستجو برای: tp53 mutation and expression

تعداد نتایج: 16973495  

Journal: :Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005
Paul C Turner Abdoulaye Sylla Shuang-Yuan Kuang Clare L Marchant Mamadou S Diallo Andrew J Hall John D Groopman Christopher P Wild

Infection with hepatitis viruses and chronic exposure to high levels of dietary aflatoxins are the major etiologic agents for hepatocellular carcinoma in west Africa. A challenge for the prevention of hepatocellular carcinoma in this region is that both hepatitis B virus and aflatoxin exposures start early in life; indeed, aflatoxin exposures can start in utero and continue unabated throughout ...

2009
Ludmila Rocnova Boris Tichy Petr Kuglik Vladimira Vranova Sona Cejkova Miluse Svitakova Hana Skuhrova Francova Yvona Brychtova Michael Doubek Martin Brejcha Martin Klabusay Jiri Mayer Sarka Pospisilova Martin Trbusek

Deletion of TP53 gene, under routine assessment by fluorescence in situ hybridization analysis, connects with the worst prognosis in chronic lymphocytic leukemia (CLL). The presence of isolated TP53 mutation (without deletion) is associated with reduced survival in CLL patients. It is unclear how these abnormalities are selected and what their mutual proportion is. We used methodologies with si...

2016
Reva K. Basho Debora de Melo Gagliato Naoto T. Ueno Chetna Wathoo Huiqin Chen Maryam Shariati Caimiao Wei Ricardo H. Alvarez Stacy L. Moulder Aysegul A. Sahin Sinchita Roy-Chowdhuri Mariana Chavez-MacGregor Jennifer K. Litton Vincent Valero Raja Luthra Jia Zeng Kenna R. Shaw John Mendelsohn Gordon B. Mills Debu Tripathy Funda Meric-Bernstam

BACKGROUND Identifying the clinical impact of recurrent mutations can help define their role in cancer. Here, we identify frequent hotspot mutations in metastatic breast cancer (MBC) patients and associate them with clinical outcomes. PATIENTS AND METHODS Hotspot mutation testing was conducted in 500 MBC patients using an 11 gene (N = 126) and/or 46 or 50 gene (N = 391) panel. Patients were s...

Journal: :Clinical genetics 2012
S S Choong Z A Latiff M Mohamed L L W Lim K S Chen L Vengidasan H Razali E J Abdul Rahman H Ariffin

Li-Fraumeni syndrome (LFS) is a highly penetrant, autosomal dominant disorder where affected individuals carry a 50% risk of developing cancer before 30 years of age. It is most commonly associated with mutations in the tumour suppressor gene, TP53. Adrenocortical carcinoma (ACC) is a very rare paediatric cancer, and up to 80% of affected children are found to carry germline TP53 mutations. Hen...

2015
Georgina E. Menzies Simon H. Reed Andrea Brancale Paul D. Lewis

The mutational pattern for the TP53 tumour suppressor gene in lung tumours differs to other cancer types by having a higher frequency of G:C>T:A transversions. The aetiology of this differing mutation pattern is still unknown. Benzo[a]pyrene,diol epoxide (BPDE) is a potent cigarette smoke carcinogen that forms guanine adducts at TP53 CpG mutation hotspot sites including codons 157, 158, 245, 24...

2015
Jill E. Kucab Harry van Steeg Mirjam Luijten Heinz H. Schmeiser Paul A. White David H. Phillips Volker M. Arlt

Somatic mutations in the tumour suppressor gene TP53 occur in more than 50% of human tumours; in some instances exposure to environmental carcinogens can be linked to characteristic mutational signatures. The Hupki (human TP53 knock-in) mouse embryo fibroblast (HUF) immortalization assay (HIMA) is a useful model for studying the impact of environmental carcinogens on TP53 mutagenesis. In an eff...

2011
M Le Garff-Tavernier H Blons F Nguyen-Khac M Pannetier M Brissard S Gueguen F Jacob L Ysebaert S A Susin H Merle-Béral

Several prognostic factors are used in chronic lymphocytic leukemia (CLL) to predict disease progression at diagnosis and to help guide therapeutic choices. Among these factors, the detection of deletions of the short arm of chromosome 17, where the tumor suppressor gene TP53 is located at the 17p13 locus, predicts resistance to standard treatments and poor prognosis. Deletions of 17p13 are obs...

Journal: :Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007
Leah E Mechanic Elise D Bowman Judith A Welsh Mohammed A Khan Nobutoshi Hagiwara Lindsey Enewold Peter G Shields Laurie Burdette Stephen Chanock Curtis C Harris

Lung cancer is primarily caused by tobacco smoking, but susceptibility is likely modified by common genetic variation. In response to many forms of cellular stress, including DNA damage, the p53 protein functions to induce cell cycle arrest, DNA repair, senescence, or apoptosis. We hypothesized that common TP53 haplotypes modulate pathways of lung carcinogenesis and lung cancer susceptibility o...

Journal: :Cancer research 2015
Maria Schwaederlé Vladimir Lazar Pierre Validire Johan Hansson Ludovic Lacroix Jean-Charles Soria Yudi Pawitan Razelle Kurzrock

Bevacizumab is one of the most widely used antiangiogenic drugs in oncology, but the overall beneficial effects of this VEGF-A targeting agent are relatively modest, in part due to the lack of a biomarker to select patients most likely to respond favorably. Several molecular aberrations in cancer influence angiogenesis, including mutations in the tumor suppressor gene TP53, which occur frequent...

Journal: :Blood 2002
Ke Lin Paul D Sherrington Michael Dennis Zoltan Matrai John C Cawley Andrew R Pettitt

Established adverse prognostic factors in chronic lymphocytic leukemia (CLL) include CD38 expression, relative lack of IgV(H) mutation, and defects of the TP53 gene. However, disruption of the p53 pathway can occur through mechanisms other than TP53 mutation, and we have recently developed a simple screening test that detects p53 dysfunction due to mutation of the genes encoding either p53 or A...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید